Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer

Inclusion criteria

Inclusion: * Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural effusions, or Stage IV NSCLC or recurrent NSCLC * No previous chemotherapy for NSCLC * Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT greater than 1 cm in diameter * Specified lab parameters * Life expectancy of at least 12 weeks * ECOG performance status of 0 or 1 * Understand requirements of study * Agree to use effective contraceptive methods Exclusion: * Have CNS metastases * Have any active cancer in addition ot NSCLC * Participated in clinical trial involving conventional or investigational drugs within previous 4 weeks * Have any contraindication to paclitaxel or carboplatin * Have had Grade 3 or greater peripheral neuropathies * Be pregnant or lactating * Have a history of myocardial infarction or angina pectoris/angina in the last 6 months * Have had significant (30 mL or more) hemoptysis with the past 3 months * Have an active infection * Have a history of bleeding diathesis, hypercoagulable condition, or an active bleeding disorder * Be receiving concurrent treatment with therapeutic doses of heparin or coumadin * Have had major surgery within 4 weeks of stating therapy * Have additional uncontrolled serious medical conditions or psychiatric illness * Received rhAngiostatin in other clinical protocols